Webinar: Learning from the Pandemic to Accelerate AAV-based Gene Therapies
February 22, 2022
On Thursday, March 17th, Fierce Biotech and Cytiva present a webinar on applying lessons from the COVID-19 pandemic to accelerate the production and development of adeno-associated virus (AAV)-based gene therapies, hosted by Yasser Kehail of Cytiva. Although challenges face the industry, the events of the past two years show how a drug can go from concept to protecting the wellbeing of hundreds of millions of patients in less than a year.
According to Cytiva, “Yasser has over 12 years of experience in cell culture manufacturing, development, and optimization. He currently supports clients working on different therapeutic modalities, such as monoclonal antibodies, plasmid DNA, vaccines, and viral vectors, consulting specifically on upstream scale-up strategies and technology transfer. Yasser began his career in cell culture manufacturing at Biogen. He then moved to Upstream PD at Amgen before joining Cytiva, formerly part of GE Healthcare’s Life Sciences business, in 2014.”
Register and find local times by clicking here.
(Source: Cytiva/Fierce Biotech, February 21th, 2022)